Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,56,425 Cr, it ranks #15 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,880.00 (as of 16 Nov 2026), the share price is 8.2% below its 52-week high of ₹2,046.90 and 18.7% above its 52-week low of ₹1,583.70. The share price is up 11.2% over one year and down 2.7% over three months.
| Current Price | ₹1,880.00 |
|---|---|
| Market Cap | ₹4,56,425 Cr |
| NSE Symbol | SUNPHARMA |
| BSE Code | 524715 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 39.5 |
| Return on Equity | 14.72% |
| Return on Assets | 8.47% |
| 52-Week Range | ₹1,583.70 – ₹2,046.90 |
| 1-Year Price Change | +11.2% |
| 3-Month Price Change | -2.7% |
| Beta (1Y) | -0.19 |
| Dividend Yield | 0.53% |
| Headquarters | Mumbai, Maharashtra |
| Website | sunpharma.com |
| Revenue | ₹16,199 Cr |
|---|---|
| Net Profit | ₹1,995 Cr |
| Net Margin | 12.3% |
| EPS (Basic) | ₹8.30 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 Cr in Q2 FY27, up 11.9% from ₹14,478 Cr in Q2 FY26 and up 5.9% from ₹15,300 Cr in Q1 FY27. It posted a net profit of ₹1,995 Cr for the quarter, against a net profit of ₹3,125 Cr in Q2 FY26 (down 36.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹12,959 Cr (Q4 FY25) to ₹16,199 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹16,199 Cr | ₹1,995 Cr | 12.3% |
| Q1 FY27 | ₹15,300 Cr | ₹2,901 Cr | 19.0% |
| Q4 FY26 | ₹14,612 Cr | ₹2,710 Cr | 18.5% |
| Q3 FY26 | ₹15,521 Cr | ₹3,381 Cr | 21.8% |
| Q2 FY26 | ₹14,478 Cr | ₹3,125 Cr | 21.6% |
| Q1 FY26 | ₹13,851 Cr | ₹2,293 Cr | 16.6% |
| Q4 FY25 | ₹12,959 Cr | ₹2,154 Cr | 16.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 52.68% of Sun Pharmaceutical Industries Limited's shares as of Sept 2026, against 54.48% in Sept 2025 (−1.80 percentage points). Delivery averaged 58.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its p
1. Pharmaceuticals-This segment manufactures, develops, and markets branded and generic formulations, and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Glenmark Pharmaceuticals Limited | ₹75,556 Cr | 55.1 | 14.07% | ₹4,157 Cr | +45.7% |
Listed by market capitalisation. Ratios are shown for context only.
Sun Pharmaceutical Industries Limited is trading at ₹1,880.00, with a market capitalisation of ₹4,56,425 Cr.
Sun Pharmaceutical Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Sun Pharmaceutical Industries Limited has a P/E of 39.5 and a return on equity of 14.72%.
Sun Pharmaceutical Industries Limited is listed on the NSE under the symbol SUNPHARMA and on the BSE under the scrip code 524715.
Sun Pharmaceutical Industries Limited's share price is up 11.2% over one year and down 2.7% over three months. Its 52-week range is ₹1,583.70 to ₹2,046.90.
In Q2 FY27, Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 Cr and net profit of ₹1,995 Cr, with basic EPS of ₹8.3 (consolidated, parsed from the company's exchange filing).
Sun Pharmaceutical Industries Limited reported revenue of ₹16,199 Cr in Q2 FY27, up 11.9% from ₹14,478 Cr in Q2 FY26 and up 5.9% from ₹15,300 Cr in Q1 FY27.
Promoters held 52.68% of Sun Pharmaceutical Industries Limited's shares as of Sept 2026, against 54.48% in Sept 2025 (−1.80 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.